N
Nicholas Brodszki
Researcher at Boston Children's Hospital
Publications - 23
Citations - 725
Nicholas Brodszki is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Primary immunodeficiency & Immunodeficiency. The author has an hindex of 9, co-authored 21 publications receiving 457 citations. Previous affiliations of Nicholas Brodszki include Lund University.
Papers
More filters
Journal ArticleDOI
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study
Elodie Elkaim,Elodie Elkaim,Benedicte Neven,Benedicte Neven,Benedicte Neven,Julie Bruneau,Julie Bruneau,Kanako Mitsui-Sekinaka,Aurélie Stanislas,Lucie Heurtier,Lucie Heurtier,Carrie L. Lucas,Helen F. Matthews,Marie Céline Deau,Marie Céline Deau,Svetlana O. Sharapova,James Curtis,Janine Reichenbach,Catherine Glastre,David A. Parry,Gururaj Arumugakani,Elizabeth M. McDermott,Sara Sebnem Kilic,Motoi Yamashita,Despina Moshous,Despina Moshous,Despina Moshous,Hicham Lamrini,Hicham Lamrini,Burkhard Otremba,Andrew R. Gennery,Tanya I. Coulter,Tanya I. Coulter,Isabella Quinti,Jean Louis Stephan,Vassilios Lougaris,Nicholas Brodszki,Vincent Barlogis,Takaki Asano,Lionel Galicier,David Boutboul,Shigeaki Nonoyama,Andrew J. Cant,Kohsuke Imai,Kohsuke Imai,Capucine Picard,Capucine Picard,Sergey Nejentsev,Thierry Jo Molina,Thierry Jo Molina,Michael J. Lenardo,Sinisa Savic,Sinisa Savic,Marina Cavazzana,Marina Cavazzana,Marina Cavazzana,Alain Fischer,Anne Durandy,Anne Durandy,Sven Kracker,Sven Kracker +60 more
TL;DR: APDS2 is a combined immunodeficiency with a variable clinical phenotype and immunoglobulin replacement therapy, rapamycin, and, likely in the near future, selective phosphoinositide 3-kinase δ inhibitors are possible treatment options.
Journal ArticleDOI
The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update
Marcus Maurer,Markus Magerl,Stephen Betschel,Werner Aberer,Ignacio J. Ansotegui,Emel Aygören-Pürsün,Aleena Banerji,Noémi Bara,Isabelle Boccon-Gibod,Konrad Bork,Laurence Bouillet,Henrik Balle Boysen,Nicholas Brodszki,Paula J. Busse,Anette Bygum,Teresa Caballero,Mauro Cancian,Anthony J. Castaldo,Danny M. Cohn,Dorottya Csuka,Henriette Farkas,Mark Gompels,Richard G. Gower,Anete Sevciovic Grumach,Guillermo Guidos-Fogelbach,Michihiro Hide,Hye Ryun Kang,Allen P. Kaplan,Constance H. Katelaris,Sorena Kiani-Alikhan,Wei Li,Richard F. Lockey,Hilary Longhurst,William R. Lumry,Andrew J. MacGinnitie,Alejandro Malbrán,Inmaculada Martinez-Saguer,J.J. Matta Campos,Alexander Nast,Dinh Nguyen,Sandra Nieto‐Martinez,Ruby Pawankar,J P Gogan Peter,Grzegorz Porebski,N. Prior,Avner Reshef,Marc A. Riedl,Bruce Ritchie,Farrukh Sheikh,William B. Smith,Peter J. Spaeth,Marcin Stobiecki,E. Toubi,Lilian Varga,Karsten Weller,Andrea Zanichelli,Yuxiang Zhi,Bruce L. Zuraw,Timothy J. Craig +58 more
TL;DR: The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of H AE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1/2 (type 2).
Journal ArticleDOI
A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls
Timo Vesikari,Nicholas Brodszki,Pierre Van Damme,Javier Díez-Domingo,Giancarlo Icardi,Lone Kjeld Petersen,Clément Tran,Stéphane Thomas,Alain Luxembourg,Martine Baudin +9 more
TL;DR: In addition to immune responses to HPV 31/33/45/52/58, a 3-dose regimen of the 9vHPV vaccine elicited a similar immune response to HPV 6/11/16/18 when compared with the qHPV vaccines in girls aged 9–15 years.
Journal ArticleDOI
A novel treatment approach for paediatric Gorham-Stout syndrome with chylothorax.
Nicholas Brodszki,John-Kalle Länsberg,Michael Dictor,Erik Gyllstedt,Sven-Börje Ewers,Marcus Larsson,Erik A. Eklund +6 more
TL;DR: Aim: To expand the treatment options in paediatric Gorham–Stout syndrome (GSS) when conventional therapy is ineffective.
Journal ArticleDOI
Diagnosis of immunodeficiency caused by a purine nucleoside phosphorylase defect by using tandem mass spectrometry on dried blood spots
Giancarlo la Marca,Giancarlo la Marca,Clementina Canessa,Elisa Giocaliere,Elisa Giocaliere,Francesca Romano,Sabrina Malvagia,Sabrina Malvagia,Silvia Funghini,Silvia Funghini,Maria Moriondo,Claudia Valleriani,Francesca Lippi,Daniela Ombrone,Daniela Ombrone,Maria Luisa Della Bona,Maria Luisa Della Bona,Carsten Speckmann,Stephan Borte,Stephan Borte,Nicholas Brodszki,Andrew R. Gennery,Katja G. Weinacht,Katja G. Weinacht,Fatih Celmeli,Julia Pagel,Maurizio de Martino,Renzo Guerrini,Helmut Wittkowski,Ines Santisteban,Pawan Bali,Aydan Ikinciogullari,Michael S. Hershfield,Luigi D. Notarangelo,Massimo Resti,Chiara Azzari +35 more
TL;DR: TMS identifies newborns with PNP deficiency, whereas TREC or KREC measurement alone can fail, and TMS is a valid method for diagnosis on DBSs of affected patients at a negligible cost.